About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

Notes to editors

This survey of members of the Association of the British Pharmaceutical Industry (ABPI) was conducted online between 23 – 28 March 2017, with 32 out of 58 members responding.

When asked about the impact of the introduction of a new £20m Budget Impact Test:

  • 71% of pharmaceutical companies who answered said 'Yes' other countries in Europe may be prioritised over the UK for the launch of new medicines
    • 11% said 'No', 18% said 'Don't know'
       
  • 89% of pharmaceutical companies who answered said patient access to cost-effective medicines in the UK will 'Decrease'
    • 0% said 'Increase', 7% said 'See no change', 4% said 'Don't know'
       
  • When presented with multiple choice list of disease/therapy areas, 75% of pharmaceutical companies who answered said new cancer medicines and treatments would be, followed by immunological (40%), neurological (40%), dementia (36%) and cardiovascular (28%)

When asked about the impact of changes to the Highly Specialised Treatments programme:

  • 75% of pharmaceutical companies who answered said 'Yes' other countries in Europe will be prioritised over the UK in launching medicines for rare diseases
    • 19% said 'No', 6% said 'Don't know'

  • 88% of pharmaceutical companies who answered said patient access to cost-effective medicines in the UK will 'Decrease'
    • 0% said 'Increase', 12% said 'See no change', 0% said 'Don't know'
       
  • When presented with a multiple choice list of disease/therapy areas, 40% of pharmaceutical companies who answered said new treatments for genetic conditions would be impacted, followed by cancer (33%), neurological (33%), metabolic (33%) and musculoskeletal (27%)

When asked about the impact of a new £20m Budget Impact Test and changes to the Highly Specialised Treatments programme:

  • No pharmaceutical companies who answered said patients access to cost-effective medicines will improve in the UK as a result of these changes

References    

  1. Office of Health Economics analysis of QuintilesIMS, 'Pricing and Market Access 2017', accessed 30 March 2017: http://www.imshealth.com/en/thought-leadership/pricing-and-market-access-outlook-2017
  2. NICE, 'Consultation on changes to technology appraisals and highly specialised technologies', October 2016, accessed 29 March 2017: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/consultation-on-changes-to-technology-appraisals-and-highly-specialised-technologies
  3. NHS England, 'Patients to get faster access to the most cost effective treatments under proposed changes to NICE process', October 2016, accessed 29 March 2017: https://www.england.nhs.uk/2016/10/proposed-changes/
  4. Office for Life Sciences, 'Life Science Competitiveness Indicators', May 2016, accessed 29 March 2017: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/523269/BIS-16-236-Office-for-Life-Sciences-OLS-life-science-competitiveness-indicators-report-May-2016.pdf
  5. Office of Health Economics, 'Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries', accessed 29 March 2017: https://www.ohe.org/publications/comparing-access-orphan-medicinal-products-omps-united-kingdom-and-other-european
  6. NHS England, 'Next steps on the NHS Five Year Forward View: Cancer', 31 March 2017, accessed 31 March 2017: https://www.england.nhs.uk/five-year-forward-view/next-steps-on-the-nhs-five-year-forward-view/cancer/  
  7. NICE, 'Consultation on changes to technology appraisals and highly specialised technologies', October 2016, accessed 29 March 2017: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/consultation-on-changes-to-technology-appraisals-and-highly-specialised-technologies
  8. The Conservative Party, 'Manifesto 2015', page 39, accessed 31 March 2017: https://s3-eu-west-1.amazonaws.com/manifesto2015/ConservativeManifesto2015.pdf

Media enquiries


+44 (0) 20 7747 7147​​